Adjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer: Current Advances and Future Perspectives.

Cancers (Basel) · 2025 · PMC12249390 · PMID 40647398

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significancep = 0.14not close (p > 0.1)

Interestingly, in the PD-L1 tumor proportion score (TPS) ≥50% subgroup, the DFS difference did not reach statistical significance (HR 0.82; 95% CI 0.57–1.18; p = 0.14), highlighting potential variability in predictive biomarker performance across different ICIs.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.